Reviewing Stemline Therapeutics Inc. (STML)’s and Harpoon Therapeutics Inc. (NASDAQ:HARP)’s results

Stemline Therapeutics Inc. (NASDAQ:STML) and Harpoon Therapeutics Inc. (NASDAQ:HARP) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Stemline Therapeutics Inc. 14 26.27 N/A -3.04 0.00
Harpoon Therapeutics Inc. 13 94.10 N/A -1.50 0.00

Demonstrates Stemline Therapeutics Inc. and Harpoon Therapeutics Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 represents Stemline Therapeutics Inc. (NASDAQ:STML) and Harpoon Therapeutics Inc. (NASDAQ:HARP)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Stemline Therapeutics Inc. 0.00% -127.1% -98.9%
Harpoon Therapeutics Inc. 0.00% 0% 0%

Liquidity

The current Quick Ratio of Stemline Therapeutics Inc. is 5 while its Current Ratio is 5.1. Meanwhile, Harpoon Therapeutics Inc. has a Current Ratio of 11.8 while its Quick Ratio is 11.8. Harpoon Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Stemline Therapeutics Inc.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for Stemline Therapeutics Inc. and Harpoon Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Stemline Therapeutics Inc. 0 0 2 3.00
Harpoon Therapeutics Inc. 0 0 0 0.00

Stemline Therapeutics Inc.’s upside potential is 168.77% at a $29 consensus target price.

Institutional and Insider Ownership

Stemline Therapeutics Inc. and Harpoon Therapeutics Inc. has shares held by institutional investors as follows: 79.9% and 55.5%. About 8.7% of Stemline Therapeutics Inc.’s share are held by insiders. Competitively, 0.5% are Harpoon Therapeutics Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Stemline Therapeutics Inc. -1.12% -10.82% -11.65% 24.02% -11.24% 39.68%
Harpoon Therapeutics Inc. 0.27% 11.37% 28.36% 0% 0% 10.3%

For the past year Stemline Therapeutics Inc.’s stock price has bigger growth than Harpoon Therapeutics Inc.

Summary

Harpoon Therapeutics Inc. beats Stemline Therapeutics Inc. on 5 of the 8 factors.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer. In addition, it develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.